Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Reports 21-Percent Rise in Q1 Revenue as R&D Spend Grows and Loss Narrows

NEW YORK, May 10 (GenomeWeb News) - Caliper Life Sciences today said that total revenues in the first quarter grew 21.2 percent as R&D spending jumped 13 percent and net loss declined.


Total receipts for the three months ended March 31 increased to $22.3 million from $18.4 million year over year. The company said product revenues increased 13 percent to $14.7 million, service revenue jumped 52 percent to $5 million, and receipts from license fees and contracts rose 3 percent to $2.6 million.


However, Caliper said "excluding unfavorable effects of foreign exchange rate movements," revenues increased from the prior year quarter by 24 percent, which includes 11 percent organic growth.


Caliper said it spent around $4.5 million on R&D, a 13-percent increase over the $4 million it spent one year ago.


Net loss in the period declined to $4.4 million, or $.13 per share, from $4.9 million, or $.16 per share, year over year.


Caliper said it had around $7 million in cash and equivalents as of March 31.


The company expects to generate between $22 million and $24 million in revenue for the second quarter, which would be improvements of between 8.3 percent and 18.2 percent year over year.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.